Showing posts with label Psoriasis Market. Show all posts
Showing posts with label Psoriasis Market. Show all posts

Monday, 14 January 2019

Psoriasis Market Size in Global Industry : Development, Research and Forecast 2019

ResearchMoz presents professional and in-depth study of "Competitor Landscape: Psoriasis".

Summary

Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Psoriasis (PsO) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1978213

- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Key Highlights

- Certolizumab pegol may find a niche in PsO patients looking to conceive, due to its global approval for use in women of childbearing age
- Novartis seeks to identify additional points of differentiation for secukinumab vs. competing biologics by further exploring efficacy and safety in pediatrics and alternative dosing formulations & strategies
- BMS-986165 could become the first TYK-2 inhibitor to be approved for PsO, pending positive data from the recently registered Phase III trials.

Scope

- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/competitor-landscape-psoriasis-report.html/toc

Reasons to buy

- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Companies mentioned
Novan
Novartis
Noxopharm
Nuevolution
Ortho Dermatologics
Pfizer
Polichem S.A.
Promius Pharma
Prothena Corporation
Realm Therapeutics
Reata Pharmaceuticals
Rigel
Saniona
Sareum
Sienna Biopharmaceuticals
Sun Pharma
Syntrix
Takeda
Theramab
Tianjin Hemay Bio-Tech
UCB

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1978213

Valeant Pharmaceuticals
Vitae Pharmaceuticals
XenoPort
Zai Lab
Ziarco Pharma

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Wednesday, 15 November 2017

Technological Advancements Of Psoriasis Market with Focus on Plaque Psoriasis 2017

ResearchMoz presents professional and in-depth study of "Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020".

Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=748522

It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It is an autoimmune disease and may be triggered by smoking, alcohol consumption, cold or dry weather and stress.

In the wake of lesser treatment options and costly therapies, psoriasis remains as an under treated disease. Psoriasis treatment can be divided into three main groups: topical treatment, light therapy, and systemic medication based on the severity of the disease. The typical treatment options include TNF inhibitors and IL inhibitors. However, various therapies and drugs are in the pipeline and it is expected that treatment options will improve over time with higher efficacy and lower costs.

The global market for psoriasis has been increasing consistently over the last few years. The major factors contributing to the growth of the global psoriasis market are increasing smoking and alcohol consumption trends globally. Surging smoking population, increased spending on medicines, increasing sales of prescription drugs and escalating health care expenditure are the key growth drivers of the market. However, growth of the market is hindered by extensive drug development and approval process and side-effects associated with the existing medication for psoriasis.

Various treatment methods are readily used to control psoriasis in the US, such as TNFs, systemics and topicals. With relatively higher prevalence rates in the US, several companies are trying to grab larger market shares with their new and innovative drugs. Plaque psoriasis is a common form of this disease in the US with increasing prevalence each year.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-psoriasis-market-with-focus-on-plaque-psoriasis-outlook-to-2020-report.html/toc

The report “Global Psoriasis Market” analyzes the development of this market, with focus on the US treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Johnson and Johnson, Abbvie inc., Amgen Inc. and Novartis are being profiled along with their key financials and strategies for growth. 

Table of Content

1. Market Overview
1.1 Psoriasis   
1.2 Types   
1.2.1 Plaque Psoriasis   
1.2.2 Guttate Psoriasis   
1.2.3 Inverse Psoriasis   
1.2.4 Pustular Psoriasis   
1.2.5 Erytherodermic Psoriasis   
1.3 Causes   
1.4 Symptoms by Types   
1.4.1 Plaque Psoriasis   
1.4.2 Guttate Psoriasis   
1.4.3 Inverse Psoriasis   
1.4.4 Pustular Psoriasis   
1.4.5 Erytherodermic Psoriasis   
1.5 Diagnosis   
1.6 Treatment Options   
1.6.1 Topical Treatments   
1.6.2 Light Therapy or Phototherapy   
1.6.3 Systemic Treatments

2. Global Market
2.1 Global Psoriasis Market by Value   
2.2 Global Psoriasis Market by Therapy

Browse Report @ https://www.researchmoz.us/global-psoriasis-market-with-focus-on-plaque-psoriasis-outlook-to-2020-report.html

3. The US Market
3.1 Autoimmune Disease Market   
3.1.1 The US Autoimmune Disease Market by Value   
3.2 Psoriasis Market   
3.2.1 The US Psoriasis Prevalence   

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/